Crystallin

Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Elasticity, ARVO, Therapy, Crystallin, Cataract, Eye, Presbyopia, Quality of life, Annual general meeting, Visu, Pharmaceutical industry, Ophthalmology

Visus Therapeutics Inc. , a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting , to be held April 23-27, 2023 in New Orleans, Louisiana.

Key Points: 
  • Visus Therapeutics Inc. , a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting , to be held April 23-27, 2023 in New Orleans, Louisiana.
  • The presentations will highlight new research findings on the Company’s alpha-crystallin aggregation inhibitor assets.
  • Alpha-crystallin aggregation inhibitors are intended to restore elasticity and lens clarity, potentially reversing presbyopia and cataracts without the need for surgery.
  • “We are pleased to share these scientific findings with the ophthalmic research community at ARVO 2023,” said Rhett Schiffman, M.D., M.S., M.H.S.A., co-founder, chief medical officer and head of research and development at Visus Therapeutics.

Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets

Retrieved on: 
Wednesday, September 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Other Health, American Academy, MHSA, Therapy, Human, Ageing, Twitter, MD, Cataract, Prevalence, NYU Langone Health, Glaucoma, LinkedIn, Population, Acquisition, Wound healing, Crystallin, Primate, Presbyopia, MS, Patient, Eye, University Medical Center, Instagram, Quality of life, Research, ViewPoint, American Academy of Ophthalmology, Elasticity, Pharmaceutical industry, Visu, Ophthalmology

Visus Therapeutics Inc., (Visus) a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc. (ViewPoint).

Key Points: 
  • Visus Therapeutics Inc., (Visus) a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc. (ViewPoint).
  • Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation inhibitors as investigational non-surgical treatments to correct protein misfolding in the lens.
  • The ViewPoint acquisition provides an extensive library of potent drug candidates with highly desirable pharmaceutical properties for ocular delivery, said Dr. Schiffman.
  • In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration.

Plex Pharmaceuticals Awarded $1.6 Million in Grant Funding from NIH to Advance Eye Drop Therapy for Cataracts

Retrieved on: 
Wednesday, July 8, 2020
Ophthalmology, Senses, Perception, Crystallin, Lens, Cataract, Small Business Innovation Research, National Institutes of Health

SAN DIEGO, July 8, 2020 /PRNewswire/ --Plex Pharmaceuticals, Inc. ("Plex"), announced that it has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) National Eye Institute: a $1.3 million Phase II grant (R44EY027236) and a $300,000 Phase I grant (R43EY031609).

Key Points: 
  • SAN DIEGO, July 8, 2020 /PRNewswire/ --Plex Pharmaceuticals, Inc. ("Plex"), announced that it has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) National Eye Institute: a $1.3 million Phase II grant (R44EY027236) and a $300,000 Phase I grant (R43EY031609).
  • CAP4196 and CAP4349 are topical eye drop formulations that act as modulators of the eye lens protein, alpha-A-crystallin (AAC).
  • AAC is a major component of the eye lens that helps maintain its transparency.
  • Loss of AAC function leads to the aggregation of damaged and/or aged proteins in the eye lens, which results in the formation of cataracts.